Table 1.
Socio‐demographic and clinical characteristics of study participants at pre‐enrolment
| Total ( n = 161) | |
|---|---|
| Clinic | |
| University Teaching Hospital of Yaoundé | 73 (45.3%) |
| Essos Medical Center | 11 (6.8%) |
| Military Hospital of Yaoundé | 8 (5.0%) |
| Cathedrale Medical Center | 22 (13.7%) |
| Central Hospital of Yaoundé | 19 (11.8%) |
| General Hospital of Yaoundé | 28 (17.4%) |
| Socio‐demographic characteristics | |
| Age (median, [IQR]) | 61.3 [55.9–66.9] |
| Female sex | 105 (65.2%) |
| Living in Yaoundé | 154 (95.7%) |
| Marital status | |
| Married | 95 (59.0%) |
| Widowed | 42 (26.1%) |
| Single | 20 (12.4%) |
| Divorced | 4 (2.5%) |
| Employment status | |
| Civil servant | 28 (17.4%) |
| Employed in private sector | 17 (10.6%) |
| Self‐employed | 19 (11.8%) |
| Unemployed | 80 (49.7%) |
| Other | 17 (10.6%) |
| Poverty Probability Index Cameroon (median, [IQR])† | 66 [59–74] |
| Clinical characteristics | |
| HIV‐positive | 11 (6.8%) |
| CD4 cell count if HIV‐positive (median, [range]) | 645 [385–1260] |
| ART regimen if HIV‐positive | |
| TDF/3TC/EFV | 4 (36.4%) |
| AZT/3TC/NVP | 1 (9.1%) |
| TDF/3TC/NVP | 1 (9.1%) |
| TDF/3TC/ATV | 4 (36.4%) |
| ABC/3TC/EFV | 1 (9.1%) |
| HCV genotype and subtype distribution per genotype | |
| Genotype 1 | 56 (34.8%) |
| 1a | 4 (7.1%) |
| 1b | 14 (25.0%) |
| 1e | 13 (23.2%) |
| 1h | 2 (3.6%) |
| 1l | 7 (12.5%) |
| 1 subtype nontypeable | 15 (26.8%) |
| 1 subtype unknown | 1 (1.8%) |
| Genotype 2 | 22 (13.7%) |
| 2a | 1 (4.5%) |
| 2f | 2 (9.1%) |
| 2a/c | 4 (18.2%) |
| 2 subtype nontypeable | 15 (68.2%) |
| Genotype 4 | 82 (50.9%) |
| 4e | 1 (1.2%) |
| 4f | 50 (60.9%) |
| 4p | 6 (7.3%) |
| 4t | 3 (3.7%) |
| 4a/e | 1 (1.2%) |
| 4a/c/d | 4 (4.9%) |
| 4 subtype nontypeable | 16 (19.5%) |
| 4 subtype unknown | 1 (1.2%) |
| Genotypes 1 and 4 | 1 (0.6%) |
| 1e and 4 subtype nontypeable | 1 (100%) |
| Median HCV RNA (log10 IU/mL [IQR])‡ | 6.0 [5.6–6.4] |
| Median aspartate aminotransferase (IU/mL [IQR]) | 44 [34–61] |
| Median alanine aminotransferase (IU/mL [IQR]) | 46 [35–63] |
| Albumin < 3.5 g/dL | 0 (0%) |
| Platelet count < 90 000 per µL | 4 (2.5%) |
| Aspartate aminotransferase‐to‐platelet ratio index | |
| ≤1.0 | 128 (79.5%) |
| >1.0 to ≤ 2.0 | 19 (11.8%) |
| >2.0 | 14 (8.7%) |
| FibroTest score | |
| F0–F2 | 82 (50.9%) |
| F3 | 29 (18.0%) |
| F4 | 50 (31.1%) |
| ActiTest score | |
| A0–A1 | 101 (62.7%) |
| A2 | 33 (20.5%) |
| A3 | 27 (16.8%) |
ABC, abacavir; ART, antiretroviral therapy; AZT, zidovudine; EFV, efavirenz; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IQR, interquartile range; IU, international units; NVP, nevirapine; RNA, ribonucleic acid; TDF, tenofovir disoproxil fumarate; 3TC, lamivudine.
†
28 missing.
‡
1 missing.